| The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients D Donnelly, S Bajaj, J Yu, M Hsu, A Balar, A Pavlick, J Weber, I Osman, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 80 | 2019 |
| Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor–based therapy in patients with advanced non–small-cell lung cancer L Sun, M Hsu, RB Cohen, CJ Langer, R Mamtani, C Aggarwal JAMA oncology 7 (6), 937-939, 2021 | 54 | 2021 |
| Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: Clinical trial evidence and experience M Crist, G Iyer, M Hsu, WC Huang, AV Balar Therapeutic Advances in Urology 11, 1756287219839285, 2019 | 18 | 2019 |
| PD-1/PD-L1 combinations in advanced urothelial cancer: rationale and current clinical trials MM Hsu, AV Balar Clinical Genitourinary Cancer 17 (3), e618-e626, 2019 | 13 | 2019 |
| The relationship between obesity and immunotherapy: It's complicated. DMA Donnelly, S Bajaj, J Zhong, JS Weber, AC Pavlick, AV Balar, M Hsu, ... Journal of Clinical Oncology 37 (15_suppl), 9562-9562, 2019 | 6 | 2019 |
| Carfilzomib-induced atypical hemolytic uremic syndrome in a patient with heterozygous CFHR3/CFHR1 deletion treated with Eculizumab CW Freyer, EM Bange, S Skuli, M Hsu, J Lin, A Cuker, AD Cohen, ... Clinical Lymphoma Myeloma and Leukemia 21 (11), e845-e849, 2021 | 5 | 2021 |
| Outcomes with first-line PD-1/PD-L1 inhibition in advanced urothelial cancer: a single institution experience MM Hsu, Y Xia, A Troxel, D Delbeau, K Francese, D Leis, D Shepherd, ... Clinical genitourinary cancer 18 (3), e209-e216, 2020 | 2 | 2020 |
| Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET/CT M Hsu, X Shan, R Zhang, E Berlin, A Goel, M Agarwal, YN Wong, ... Clinical Genitourinary Cancer, 102108, 2024 | | 2024 |
| Castration-resistant prostate cancer (CRPC) on PSMA-PET: Imaging features, disease distribution, and a comparison to castration-sensitive prostate cancer (CSPC). M Hsu, X Shan, R Zhang, A Pantel, SU Takvorian, V Narayan, DJ Vaughn, ... Journal of Clinical Oncology 41 (16_suppl), e17062-e17062, 2023 | | 2023 |
| Biochemical recurrence after salvage prostate bed radiotherapy captured on PSMA-PET: Patient characteristics and distribution of recurrent disease. M Hsu, X Shan, N Vapiwala, R Zhang, A Pantel, E Berlin, V Narayan, ... Journal of Clinical Oncology 41 (16_suppl), e17088-e17088, 2023 | | 2023 |
| 18F-DCFPyL PET in first BCR and initial staging: Concordance with conventional imaging. M Hsu, X Shan, A Pantel, SU Takvorian, J Shevach, V Narayan, ... Journal of Clinical Oncology 41 (6_suppl), 58-58, 2023 | | 2023 |
| Implementing 18F-DCFPyL PET in clinical practice: Prescribing patterns and utilization at a large academic center. M Hsu, X Shan, SU Takvorian, A Pantel, V Narayan, J Shevach, ... Journal of Clinical Oncology 41 (6_suppl), 42-42, 2023 | | 2023 |
| When Clot Is Tumor: A Roadmap to Anticoagulation in Renal Cell Carcinoma With Tumor Thrombus M Hsu, N Balzer-Haas Cardio Oncology 4 (4), 532-534, 2022 | | 2022 |
